Epoetin alfa reduces anemia in breast cancer patients with no negative impact on survival
(Journal of the National Cancer Institute) In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free or overall survival. However, it can increase the risk of thrombotic events, according to a study published July 17 in the Journal of the National Cancer Institute. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 17, 2013 Category: Cancer & Oncology Source Type: news
Procrit - Epoetin Alfa – Drug To Boost...
Procrit is a man-made protein, given as a booster shot to help restart red blood cell production when chemotherapy for breast cancer causes anemia. Procrit is a very safe drug, and has few risks and side effects. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - July 7, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Amgen Fraud Suit to Proceed as Class-Action
The U.S. Supreme Court shot down an effort by Epogen-maker Amgen to disqualify a securities fraud case as a class-action suit, sending the claims back to a lower court. (Source: WSJ.com: Health)
Source: WSJ.com: Health - February 27, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news
NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
FORT WASHINGTON, Pa., December 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines relating to the use of erythropoietin-stimulating agents (ESAs), such as epoetin alfa and darbepoetin alfa.
ESAs are no longer recommended for the treatment of cancer-related anemia associated with solid tumors or hematologic malignancies other than myelodysplastic syndromes (MDS). ESA therapy is an option for patient... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 20, 2007 Category: Cancer & Oncology Source Type: news
